Updated KEYTRUDA ® (pembrolizumab) Data in Small Cell Lung Cancer and Mesothelioma Presented at 17th World Conference on Lung Cancer
Dateline City:
KENILWORTH, N.J. Findings in Small Cell Lung Cancer and Malignant Pleural Mesothelioma Show Overall Response Rates of 33.3 Percent and 20.0 Percent, Respectively, in KEYNOTE-028 Long-Term Data Demonstrate Durable Responses in Difficult-to-Treat CancersKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that updated findings from the phase 1b KEYNOTE-028
study investigating the use of KEYTRUDA® (pembrolizumab), the
company ’s anti-PD-1 therapy, in previously treated patients with
advanced small cell lung cancer (SCLC) and malignant pleural
mesothelioma, showed clinical activity and durable responses in some
patients.Language:
EnglishContact: Media:Pamela Eisele, 267-305-3558orCourtney Ronaldo, 908-236-1108orInvestorsTeri Loxam, 908-740-1986orAmy Klug, 908-740-1898Ticker Slug:Ticker:MRKExchange:NYSE
@Merckread more
Source: Merck.com - Product News - Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK Keytruda Lung Cancer MSD NYSE:MRK Source Type: news
More News: Asbestosis | Cancer | Cancer & Oncology | Conferences | Drugs & Pharmacology | Lung Cancer | Merck | Mesothelioma | Small Cell Lung Cancer | Study